Literature DB >> 10805950

Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer.

P O Chappuis1, V Nethercot, W D Foulkes.   

Abstract

Approximately 2% to 5% of all breast cancers are hereditary, meaning that the cancer predisposition is carried as a monogenic trait. Several highly penetrant breast cancer predisposing genes have been identified. These discoveries will permit a refined description of breast cancer occurring as part of the different genetic syndromes. We reviewed the medical literature on the clinico-pathological features of breast cancer associated with the major breast cancer susceptibility genes BRCA1 and BRCA2. BRCA1-associated breast cancers are more frequently ductal invasive, high-grade carcinomas with an important lymphocytic infiltration. They are aneuploid, estrogen and progesterone receptors negative, and p53 positive. BRCA2-related breast cancers tend to be higher-grade tumors than are non-hereditary cases, although this association is less strong then for BRCA1 cases. These tumors exhibit substantially less tubule formation, but mitotic count and cellular pleomorphism do not differ significantly from those of sporadic cases. The overall pattern of the identified pathological characteristics suggests a carcinogenic pathway in BRCA1- and BRCA2-related breast cancers different from that found in sporadic cases. The probability of finding a BRCA1/2 germ-line mutation is partly determined by these characteristics. In addition, these features will likely influence the behavior of BRCA1/2-related breast cancer. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805950     DOI: 10.1002/(sici)1098-2388(200006)18:4<287::aid-ssu3>3.0.co;2-5

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  42 in total

Review 1.  BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.

Authors:  William D Foulkes
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

2.  Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.

Authors:  Allison W Kurian; Bronislava M Sigal; Sylvia K Plevritis
Journal:  J Clin Oncol       Date:  2009-12-07       Impact factor: 44.544

3.  Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.

Authors:  P K Lovelock; S Healey; W Au; E Y M Sum; A Tesoriero; E M Wong; S Hinson; R Brinkworth; A Bekessy; O Diez; L Izatt; E Solomon; M Jenkins; H Renard; J Hopper; P Waring; S V Tavtigian; D Goldgar; G J Lindeman; J E Visvader; F J Couch; B R Henderson; M Southey; G Chenevix-Trench; A B Spurdle; M A Brown
Journal:  J Med Genet       Date:  2005-05-27       Impact factor: 6.318

4.  Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.

Authors:  Ava Kwong; L P Wong; H N Wong; F B F Law; E K O Ng; Y H Tang; W K Chan; D T K Suen; C Choi; L S Ho; K H Kwan; M Poon; T T Wong; K Chan; S W W Chan; M W L Ying; W C Chan; E S K Ma; J M Ford; D W West
Journal:  Hugo J       Date:  2010-04-10

5.  Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls.

Authors:  Marise R Heerma van Voss; Petra van der Groep; Jos Bart; Elsken van der Wall; Paul J van Diest
Journal:  BMC Cancer       Date:  2010-04-16       Impact factor: 4.430

Review 6.  BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.

Authors:  John J Krais; Neil Johnson
Journal:  Cancer Res       Date:  2020-08-03       Impact factor: 12.701

Review 7.  BRCA1 functions as a breast stem cell regulator.

Authors:  W D Foulkes
Journal:  J Med Genet       Date:  2004-01       Impact factor: 6.318

8.  Decreased Expression of BRCA2 Accelerates Sporadic Breast Cancer Progression.

Authors:  Soumi Saha; Pranab Mandal; Suvro Ganguly; Debarshi Jana; Asif Ayaz; Abhirup Banerjee; Rahul Chouhan; Diptendra Kumar Sarkar
Journal:  Indian J Surg Oncol       Date:  2015-08-21

Review 9.  Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.

Authors:  Dawn C Allain
Journal:  J Mol Diagn       Date:  2008-08-07       Impact factor: 5.568

10.  BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.

Authors:  Julian Puppe; Rinske Drost; Xiaoling Liu; Simon A Joosse; Bastiaan Evers; Paulien Cornelissen-Steijger; Petra Nederlof; Qiang Yu; Jos Jonkers; Maarten van Lohuizen; Alexandra M Pietersen
Journal:  Breast Cancer Res       Date:  2009-08-26       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.